Quarter

Moolec Science Presents Second Quarter Fiscal Year 2024 Business Update

Retrieved on: 
Wednesday, March 13, 2024
4M, Conference, Farmer, Growth, MLEC, Research, Seed, Genetic distance, Marketing, Plant, Conference call, Myoglobin, Quarter, Fiscal, Internet service provider

Luxembourg, Mar 13, 2024 - (ACN Newswire) - Moolec Science SA (NASDAQ:MLEC) a science-based food ingredient company focused on producing animal proteins in plants through Molecular Farming technology, announced today its Business Update for the second quarter of Fiscal Year 2024 ended December 31, 2023.

Key Points: 
  • Luxembourg, Mar 13, 2024 - (ACN Newswire) - Moolec Science SA (NASDAQ:MLEC) a science-based food ingredient company focused on producing animal proteins in plants through Molecular Farming technology, announced today its Business Update for the second quarter of Fiscal Year 2024 ended December 31, 2023.
  • The main highlights of Moolec's business update are as follows:
    - SOOY1 | Piggy Sooy(TM) Platform: Third generation (T3) soybean seed propagation has started, and fourth generation (T4) seeds are expected to be harvested in April 2024.
  • - PEEA1: Scientific team confirms the presence of bovine myoglobin gene in pea seeds and the gene's stable inheritance across plant generations.
  • Thank you to the Moolers, and to our partners for their continued support," stated Gaston Paladini, Chief Executive Officer and Co-Founder of Moolec Science.

A Dazzling Display Arrives on The Magnificent Mile: "Spectrum by Mirari"

Retrieved on: 
Thursday, April 4, 2024
Sound, Partnership, Special Service, Magnificent, Light, Social media, Quarter, Magnificent Mile, Life, Acoustics, Exhibition, Avenue

The Magnificent Mile® Association and Special Service Area 76 are thrilled to announce the arrival of "Spectrum by Mirari," a captivating interactive art installation on Chicago's famed Avenue.

Key Points: 
  • The Magnificent Mile® Association and Special Service Area 76 are thrilled to announce the arrival of "Spectrum by Mirari," a captivating interactive art installation on Chicago's famed Avenue.
  • As participants contribute their words, they'll witness their spoken messages journey across the expanse, sparking a captivating exchange of sound and light.
  • "This installation is a journey," says Kimberly Bares, President and CEO of The Magnificent Mile Association.
  • For additional information and other events on The Magnificent Mile, please visit themagnificentmile.com or join the conversation on our social media platforms.

Mural Oncology Announces Fourth Quarter and Year End 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, March 26, 2024
Research, Quarter, Patient, Pembrolizumab, Protein engineering, Nature, AACR, Cancer, Safety, Melanoma, PD-1, Pharmaceutical industry

WALTHAM, Mass. and DUBLIN, Ireland, March 26, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced its financial results for the fourth quarter and year ended December 31, 2023, and provided a business update.

Key Points: 
  • “We have made significant progress since becoming an independent company during the fourth quarter of 2023.
  • Financial Results for the Quarter Ended December 31, 2023
    Cash Position: As of December 31, 2023, cash and cash equivalents were $270.9 million.
  • G&A Expenses: General and administrative expenses were $16.3 million for the fourth quarter of 2023, including $9.7 million in non-cash, share-based compensation expenses.
  • Furthermore, the company’s 2023 financial results reflect carve-out financials until the date of the spin out.

Q2 TD Cowen/AFS Freight Index: Parcel surcharge changes wring out additional revenue, LTL and truckload rates hold steady

Retrieved on: 
Tuesday, April 9, 2024
DAS, AFS, LTL, Transport, GRI, ZIP, FedEx, Yoy, Index, Quarter, UPS, Cargo

ATLANTA, April 9, 2024 /PRNewswire/ -- AFS Logistics, an industry-leading third-party logistics (3PL) provider, and TD Cowen announce the second quarter (Q2) 2024 release of the TD Cowen/AFS Freight Index, a snapshot with predictive pricing for truckload, less-than-truckload (LTL) and parcel transportation markets. The latest release of the index expects LTL and truckload rates to remain steady, consistent with trends established since Q2 of last year. In parcel, the index shows the effect of fuel surcharge increases and other accessorial changes to drive net rate growth in Q1 and Q2 2024, despite limited overall demand.

Key Points: 
  • The latest release of the index expects LTL and truckload rates to remain steady, consistent with trends established since Q2 of last year.
  • In parcel, the index shows the effect of fuel surcharge increases and other accessorial changes to drive net rate growth in Q1 and Q2 2024, despite limited overall demand.
  • "While truckload and LTL markets are largely a continuation of established trends, parcel carriers have unleashed a wave of key pricing changes to raise revenue," says Tom Nightingale, CEO of AFS.
  • The ground parcel fuel surcharge is based on the U.S. on-highway diesel fuel index , and express is based on the U.S. Gulf Coast kerosene-type jet fuel .

Mandalay Resources Corporation Announces Strong Production Results and Growing Cash Balance for First Quarter 2024

Retrieved on: 
Monday, April 8, 2024
Quarter, TSX, Gold, Antimony, Palladium

TORONTO, April 8, 2024 /PRNewswire/ - Mandalay Resources Corporation ("Mandalay" or the "Company") (TSX: MND) (OTCQB: MNDJF) announces strong first quarter production results marked by a notable increase in cash balance.

Key Points: 
  • TORONTO, April 8, 2024 /PRNewswire/ - Mandalay Resources Corporation ("Mandalay" or the "Company") (TSX: MND) (OTCQB: MNDJF) announces strong first quarter production results marked by a notable increase in cash balance.
  • "We are pleased to report Mandalay's continued operational success in the latest quarter, achieving a solid production result of nearly 25,000 gold equivalent ounces across both operations.
  • This achievement positions the Company on a stable trajectory towards meeting our annual production target of 90,000 – 100,000 gold equivalent ounces.
  • Of significant note, Mandalay bolstered its cash reserves substantially, increasing its cash balance by over $20 million in the quarter, culminating in a closing quarter cash balance of $47 million."

Mandalay Resources Corporation Announces Strong Production Results and Growing Cash Balance for First Quarter 2024

Retrieved on: 
Monday, April 8, 2024
Quarter, The Company, TSX, Gold, Antimony, Palladium

TORONTO, April 8, 2024 /PRNewswire/ -- Mandalay Resources Corporation ("Mandalay" or the "Company") (TSX: MND) (OTCQB: MNDJF) announces strong first quarter production results marked by a notable increase in cash balance.

Key Points: 
  • TORONTO, April 8, 2024 /PRNewswire/ -- Mandalay Resources Corporation ("Mandalay" or the "Company") (TSX: MND) (OTCQB: MNDJF) announces strong first quarter production results marked by a notable increase in cash balance.
  • "We are pleased to report Mandalay's continued operational success in the latest quarter, achieving a solid production result of nearly 25,000 gold equivalent ounces across both operations.
  • This achievement positions the Company on a stable trajectory towards meeting our annual production target of 90,000 – 100,000 gold equivalent ounces.
  • Of significant note, Mandalay bolstered its cash reserves substantially, increasing its cash balance by over $20 million in the quarter, culminating in a closing quarter cash balance of $47 million."

IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on: 
Thursday, March 21, 2024
Quarter, Annual report, Medical Products Agency (Sweden), Parkinson's disease, General counsel, International, Patient, Loan agreement, Research, Webcast, Form 10-K, University, Stock, Senior, Bank statement, TSX, SKU, Investment, Pet, Cryptocurrency

SAINT LAURENT, Quebec, March 21, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the three- and twelve-month periods ended December 31, 2023.

Key Points: 
  • SAINT LAURENT, Quebec, March 21, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the three- and twelve-month periods ended December 31, 2023.
  • Net comprehensive loss was $1.7 million, down from $2.3 million in the fourth quarter of 2022.
  • Operating costs and expenses were $2.4 million for the fourth quarter of 2023, versus $2.7 million for the corresponding three-month period of 2022.
  • IntelGenx will host a conference call to discuss these 2022 fourth quarter and full year financial results today at 8:30 a.m.

LexinFintech Holdings Ltd. Reports Fourth Quarter and Full Year 2023 Unaudited Financial Results

Retrieved on: 
Wednesday, March 20, 2024
PIN, Quarter, Software as a service, Marketing, Research, Policy, PAG, Tech, Risk management, Ant Group, Senior, Credit, ASC, GMV, GAAP, LX, Growth, CFO, Table, ADS, Ecosystem, Collection, Video game

Total loan originations2 in the fourth quarter of 2023 was RMB61.2 billion, an increase of 9.2% from RMB56.1 billion in the fourth quarter of 2022.

Key Points: 
  • Total loan originations2 in the fourth quarter of 2023 was RMB61.2 billion, an increase of 9.2% from RMB56.1 billion in the fourth quarter of 2022.
  • Fourth Quarter 2023 Financial Highlights:
    Total operating revenue was RMB3,509 million, representing an increase of 15.1% from the fourth quarter of 2022.
    Credit facilitation service income was RMB2,727 million, representing an increase of 38.9% from the fourth quarter of 2022.
  • Fourth Quarter 2023 Financial Results:
    Operating revenue increased by 15.1% from RMB3,050 million in the fourth quarter of 2022 to RMB3,509 million in the fourth quarter of 2023.
    Credit facilitation service income increased by 38.9% from RMB1,964 million in the fourth quarter of 2022 to RMB2,727 million in the fourth quarter of 2023.
  • Investment loss was RMB302 million in the fourth quarter of 2023, as compared to RMB38.4 million in the fourth quarter of 2022.

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, March 20, 2024
Quarter, Disease, Patient, UPCR, Clinical trial, Therapy, EGFR, Proteinuria, FDA, BLA, Hematuria, Pharmaceutical industry

“We believe atacicept 72-week data from the Phase 2b ORIGIN trial are consistent with a profile of true disease modification.

Key Points: 
  • “We believe atacicept 72-week data from the Phase 2b ORIGIN trial are consistent with a profile of true disease modification.
  • The ORIGIN 2b results also provide us with even greater confidence in the ongoing ORIGIN Phase 3 trial, which continues to be on track with regard to enrollment,” stated Robert Brenner, M.D., Chief Medical Officer of Vera Therapeutics.
  • During the year ended December 31, 2023, net cash used in operating activities was $92.2 million, compared to $67.6 million for the same period last year.
  • Vera reported $160.7 million in cash, cash equivalents, and marketable securities as of December 31, 2023.

Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Tuesday, March 19, 2024
Research, Moyamoya disease, Quarter, Cardiovascular disease, Spirited, Growth, Exercise, Entrepreneurship, IL-6, Inflammation, Patient, SVP, Business development, Commercial, NASDAQ Biotechnology Index, MD, IND, Investment, Clinical trial, NBI, Investigational New Drug, Therapy, TRML, Medical research, Graves' ophthalmopathy, FDA, Food, Pharmaceutical industry

In October 2023, Tourmaline become a publicly-traded company via reverse merger with Talaris Therapeutics, including a concurrent private placement of $75.0 million.

Key Points: 
  • In October 2023, Tourmaline become a publicly-traded company via reverse merger with Talaris Therapeutics, including a concurrent private placement of $75.0 million.
  • Fourth Quarter and Full Year 2023 Financial Results:
    Cash, cash equivalents and investments were $203.0 million as of December 31, 2023, as compared to $8.3 million as of December 31, 2022.
  • Research and development expenses were $8.0 million for the fourth quarter of 2023, as compared to $3.8 million for the fourth quarter of 2022.
  • General and administrative expenses were $6.9 million for the fourth quarter of 2023, as compared to $1.1 million for the fourth quarter of 2022.